 - The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months RARITAN, N.J., March 31, 2021 PRNewswire -- Ortho Clinical Diagnostics Nasdaq: OCDX, one of the worlds largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority BARDA and the U.S. Department of Defense, the company been awarded an undefinitized contract which will lead to a 53.7 million contract that will support a more than three-fold increase in domestic production capabilities for its COVID-19 serological and diagnostic testing solutions. 